Supplemental Table 1.

Univariate before vs. after comparisons for NAC and AC in cN0 patients

Outcome	2000–2007 (n=92)	2008–2012 (n=84)	p value
NAC, n (%)	7 (7.6)	20 (23.8)	0.003
No. receiving NAC/year, median (range)	1 (0–2)	4 (1–7)
% receiving NAC/year, median (range)	7.9 (0.0–18.2)	26.7 (5.3–43.8)
AC, n (%)	27 (29.4)	13 (15.5)	0.03
No. receiving AC/year, median (range)	3 (2–5)	2 (1–6)
%receiving AC/year, median (range)	28.6 (18.2–50.0)	10.5 (5.6–40.0)

Use of NAC increased while use of AC decreased in cN0 patients after the initiation of the MDBCC. AC: adjuvant chemotherapy; MDBCC: multidisciplinary bladder cancer clinic; NAC: neoadjuvant chemotherapy.